Field Medical(r) Inc., a leader in pulsed field cardiac catheter ablation technology, announced today that its FieldForce(tm) Ablation System has been accepted into the FDA’s Total Product Life Cycle Advisory Program (TAP) Pilot and granted Breakthrough Device Designation for sustained monomorphic scar-related ventricular tachycardia (VT).
